12 Most Profitable Pharmaceutical Stocks Right Now

3. Takeda Pharmaceutical Company Limited (NYSE:TAK)

Net Income Growth 5Y: 28.35%

Takeda Pharmaceutical Company Limited (NYSE:TAK) is a leading global biopharmaceutical company with a rich history dating back to 1781. It is the third-largest pharmaceutical company in Asia. The company’s core mission is to discover and deliver life-transforming treatments across several therapeutic areas, including oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines.

Takeda Pharmaceutical Company Limited (NYSE:TAK) is emerging as one of the most profitable stocks because of its robust financial performance and strategic growth initiatives. In Q2 2025, the company reported a 5% revenue growth at constant exchange rates (CER), reaching ¥2.4 trillion for the first half of FY 2024, with core operating profit up 22.3% (12.9% at CER) and core EPS at ¥310. The corporation’s key growth drivers include its Growth & Launch portfolio, which grew 18.7% at CER and now accounts for 47% of total revenue. Products like ENTYVIO and new launches such as FRUZAQLA and ADZYNMA have exceeded expectations, supported by geographical expansion and efficiency programs. With a strong market position, ENTYVIO’s peak sales projected at $7.5–$9 billion, and FRUZAQLA gaining a 29% share in metastatic colorectal cancer treatment, the corporation is poised for continued growth.

Street analysts hold a Moderate Buy rating on the stock, with a 12-month price target of $14.80, representing a 9.79% increase from its current price of $13.48.